Eltrombopag Drugs Market Report 2026

Eltrombopag Drugs Market Overview

• Eltrombopag Drugs market size has reached to $2.49 billion in 2025 • Expected to grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: The Rise In Thrombocytopenia-Related Disorders Drives The Growth Of The Market Due To Increasing Autoimmune Disease Cases And Demand For Platelet-Stimulating Therapies • Market Trend: Patient-Centered Drug Delivery Solutions Transform Blood Disorder Treatments • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Eltrombopag Drugs Market?

Eltrombopag drugs refer to medications used to increase platelet counts in patients with conditions such as chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. They work by stimulating the thrombopoietin receptor to promote platelet production in the bone marrow. The main types of eltrombopag drugs are tablets and oral suspension. Eltrombopag tablets refer to an oral medication used to increase platelet counts in patients with thrombocytopenia by stimulating the production of platelets in the bone marrow. These drugs are used across several applications, including chronic immune thrombocytopenia, hepatitis C-associated thrombocytopenia, severe aplastic anemia, and others. They are distributed through multiple channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. Cater to various end users, including hospitals, clinics, homecare, and others.

What Is The Eltrombopag Drugs Market Growth Forecast?

The eltrombopag drugs market size is expected to see strong growth in the next few years. It will grow to $3.77 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to development of new oral and suspension formulations, expansion of patient-friendly dosing options, increasing adoption in homecare settings, growth in online pharmacy distribution, rising research in combination therapies for thrombocytopenia. Major trends in the forecast period include rising adoption of eltrombopag tablets and oral suspensions, growing awareness of chronic immune thrombocytopenia and related disorders, expansion of hospital and retail pharmacy distribution networks, increasing use in hepatitis c-associated thrombocytopenia and severe aplastic anemia, development of flavored and patient-friendly oral formulations.

Global Eltrombopag Drugs Market Segmentation

1) By Type: Tablets, Oral Suspension 2) By Application: Chronic Immune Thrombocytopenia, Hepatitis C-Associated Thrombocytopenia, Severe Aplastic Anemia, Other Applications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 4) By End-User: Hospitals, Clinics, Homecare, Other End-Users Subsegments: 1) By Tablets: 25 Mg Tablets, 50 Mg Tablets, 75 Mg Tablets 2) By Oral Suspension: 12.5 Mg And mL Suspension, Flavored Suspension, Reconstituted Powder Form

What Are The Drivers Of The Eltrombopag Drugs Market?

The increasing prevalence of thrombocytopenia-related disorders is expected to propel the growth of the eltrombopag drugs market going forward. Thrombocytopenia-related disorders refer to medical conditions characterized by an abnormally low platelet count in the blood, which can lead to increased bleeding, bruising, and difficulty in clot formation. The thrombocytopenia-related disorders are increasing due to the rising incidence of autoimmune diseases, as the body's immune system mistakenly destroys healthy platelets. Eltrombopag drugs help thrombocytopenia-related disorders by stimulating platelet production through activation of the thrombopoietin receptor, thereby reducing the risk of bleeding complications. For instance, in August 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, from 2022 to 2024, the proportion of people with IgM antibodies indicating recent infection increased across all age groups from less than 3% to 10% by June 2024, with the most significant rise among children aged 5 to 9 years, jumping from 15% to 40%. Therefore, the increasing prevalence of thrombocytopenia-related disorders is driving the growth of the eltrombopag drugs industry. The increasing number of clinical trials is expected to propel the growth of the eltrombopag drugs market going forward. Clinical trials refer to research studies conducted in humans to evaluate the safety, effectiveness, and outcomes of medical, surgical, or behavioural interventions. The number of clinical trials is increasing due to the rising demand for new and effective therapies to address unmet medical needs and emerging health challenges. The growing number of clinical trials enhances the development and validation of eltrombopag drugs, supporting their expanded use in treating blood disorders. For instance, in December 2024, according to the Association of the British Pharmaceutical Industry, a UK-based pharmaceutical industry trade association, the total number of industry-sponsored clinical trials initiated in the United Kingdom increased from 411 in 2022 to 426 in 2023, while Phase III trial initiations grew by 16.5 percent over the same period, rising from 182 to 212. Therefore, the increasing number of clinical trials is driving the growth of the eltrombopag drugs industry.

Key Players In The Global Eltrombopag Drugs Market

Major companies operating in the eltrombopag drugs market are Novartis AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, Hetero Labs Limited, Dr. Reddy’s Laboratories Ltd, Alkem Laboratories Ltd, Granules India Ltd, Synthon BV, Metrochem API Pvt. Ltd, Taj Pharma India Ltd, Biophore India Pharmaceuticals Pvt. Ltd, Camber Pharmaceuticals Inc, Chunghwa Chemical Synthesis And Biotech Co. Ltd., Midas Pharma GmbH, Nuray Chemicals Private Limited, MSN Laboratories Private Limited., Aprazer Healthcare Private Limited., Eskay Healthcare Private Limited.

Global Eltrombopag Drugs Market Trends and Insights

Major companies operating in the eltrombopag drugs market are focusing on developing advancements in drug formulations, such as next-generation oral formulations, to enhance patient compliance and therapeutic efficacy. Oral formulations refer to medications that are designed to be taken by mouth, such as tablets, capsules, or liquid solutions, allowing for convenient and non-invasive drug delivery. For instance, in May 2025, Camber Pharmaceuticals Inc., a US-based pharmaceutical company, launched an AB-rated generic version of Promacta eltrombopag to enhance access to cost-effective treatment for thrombocytopenia-related disorders. The product is offered in tablet form with dosage strengths of 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg, along with an oral suspension delivering a 12.5 mg/5 mL solution, designed for both pediatric and adult patients who have difficulty swallowing tablets. These formulations feature eltrombopag olamine, a thrombopoietin receptor agonist that promotes platelet production by activating the c-Mpl receptor on progenitor cells in the bone marrow.

Regional Insights

North America was the largest region in the eltrombopag drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Eltrombopag Drugs Market?

The eltrombopag drugs market consists of sales of flavored suspension and tablets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Eltrombopag Drugs Market Report 2026?

The eltrombopag drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the eltrombopag drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.